WO2000062781A1 - Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk - Google Patents
Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk Download PDFInfo
- Publication number
- WO2000062781A1 WO2000062781A1 PCT/EP2000/003578 EP0003578W WO0062781A1 WO 2000062781 A1 WO2000062781 A1 WO 2000062781A1 EP 0003578 W EP0003578 W EP 0003578W WO 0062781 A1 WO0062781 A1 WO 0062781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sgk
- kinase
- expression
- human kinase
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the h-sgk In normal intestinal tissue, the h-sgk is only expressed in the enterocytes. In Crohn's disease, however, the kinase is also found in the connective tissue.
- Fibrosive pancreatitis In the normal pancreas, the h-sgk is found in acinar cells and also in gang cells. There are isolated h-sgk-expressing mononuclear cells around the pancreatic ducts. The expression of kinase is significantly increased in fibrosing pancreatitis.
- the stimulation of the ENaC by h-sgk can be reversed by coexpression of the transdominant-inhibitory kinase: Oocytes that express ENaC and h-sgk simultaneously have much larger currents (I) than oocytes that only express ENaC. Co-expression of the transdominant-inhibitory kinase prevents stimulation of the ENaC by the h-sgk.
- the current through the MDEG (I) increases with the duration of the incubation [day (T) 1 - 4].
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0009914-7A BR0009914A (pt) | 1999-04-20 | 2000-04-19 | Medicamento, e, usos de um inibidor, e de um ativador de quinase h-sgk humana regulada por volume celular |
MXPA01010588A MXPA01010588A (es) | 1999-04-20 | 2000-04-19 | Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk. |
JP2000611917A JP2002542196A (ja) | 1999-04-20 | 2000-04-19 | 細胞容量調節ヒトキナーゼh−sgkのインヒビター含有医薬 |
AU42972/00A AU779941B2 (en) | 1999-04-20 | 2000-04-19 | Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
EP00922655A EP1171131A1 (de) | 1999-04-20 | 2000-04-19 | Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk |
PL352547A PL198427B1 (pl) | 1999-04-20 | 2000-04-19 | Zastosowanie chelerytryny |
UA2001117896A UA79066C2 (en) | 1999-04-20 | 2000-04-19 | Transdominant inhibitory kinase h-sgk in which lysine is substituted in the 127 position by arginine, and its use for preparation the remedy |
CA002369078A CA2369078A1 (en) | 1999-04-20 | 2000-04-19 | Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
SK1497-2001A SK14972001A3 (sk) | 1999-04-20 | 2000-04-19 | Liečivá obsahujúce inhibítory bunkovým objemom regulovanej ľudskej kinázy h-sgk |
NO20015054A NO20015054L (no) | 1999-04-20 | 2001-10-17 | Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19917990A DE19917990A1 (de) | 1999-04-20 | 1999-04-20 | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
DE19917990.5 | 1999-04-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/984,945 Division US20050064501A1 (en) | 1999-04-20 | 2004-11-10 | Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000062781A1 true WO2000062781A1 (de) | 2000-10-26 |
Family
ID=7905297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/003578 WO2000062781A1 (de) | 1999-04-20 | 2000-04-19 | Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1171131A1 (de) |
JP (1) | JP2002542196A (de) |
KR (1) | KR100718900B1 (de) |
CN (1) | CN1351496A (de) |
AU (1) | AU779941B2 (de) |
BR (1) | BR0009914A (de) |
CA (1) | CA2369078A1 (de) |
CZ (1) | CZ20013778A3 (de) |
DE (1) | DE19917990A1 (de) |
HU (1) | HUP0200819A3 (de) |
MX (1) | MXPA01010588A (de) |
NO (1) | NO20015054L (de) |
PL (1) | PL198427B1 (de) |
RU (1) | RU2288718C9 (de) |
SK (1) | SK14972001A3 (de) |
UA (1) | UA79066C2 (de) |
WO (1) | WO2000062781A1 (de) |
ZA (1) | ZA200108610B (de) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074987A2 (de) * | 2001-03-21 | 2002-09-26 | Florian Lang | Quantitative diagnostische analyse der hypertonie |
WO2003102206A2 (de) * | 2002-06-04 | 2003-12-11 | Florian Lang | Sgk und nedd als diagnostische und therapeutische targets |
EP1389941A2 (de) * | 2001-04-27 | 2004-02-25 | Cold Spring Harbor Laboratory | Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstörungen durch veränderung der atypischen pkm-aktivität |
WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
WO2005037773A1 (de) * | 2003-10-09 | 2005-04-28 | Merck Patent Gmbh | Acylhydrazonderivate und ihre verwendung bei der hemmung, regulierung und/oder modulation des signaltransduktion von kinasen |
WO2005094796A2 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for interfering with fibrosis |
WO2005094829A1 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
WO2005106491A2 (en) * | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
WO2006000293A1 (de) * | 2004-06-26 | 2006-01-05 | Merck Patent Gmbh | Ortho-substituierte (3-hydroxyphenyl)-essigsäure benzyliden-hydrazide |
WO2006072354A1 (de) * | 2005-01-07 | 2006-07-13 | Merck Patent Gmbh | Quadratsäurederivate |
WO2006105850A1 (de) * | 2005-04-04 | 2006-10-12 | Merck Patent Gmbh | Acylhyclrazide als kinase inhibitoren insbesondere für sgk |
WO2007014608A1 (de) * | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate ii |
WO2007022858A1 (de) * | 2005-08-22 | 2007-03-01 | Merck Patent Gmbh | 3-oxo-indazol-quadratsäurederivate |
DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
WO2010020305A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate für die behandlung von diabetes |
DE102008059133A1 (de) | 2008-11-26 | 2010-05-27 | Merck Patent Gmbh | Difluorphenyl-diacylhydrazid-derivate |
WO2012064981A3 (en) * | 2010-11-10 | 2012-08-16 | National Jewish Health | Methods to test allergic conditions |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10042137A1 (de) * | 2000-08-28 | 2002-03-14 | Florian Lang | sgk2 und sgk3 als diagnostische und therapeutische Targets |
DE10149393A1 (de) * | 2001-09-28 | 2003-04-24 | Florian Lang | sgk1 als diagnostisches und therapeutisches target |
DE10305212A1 (de) * | 2003-02-07 | 2004-08-19 | Florian Prof. Dr.med. Lang | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
JP4762552B2 (ja) * | 2003-03-03 | 2011-08-31 | フロリアン ラング、 | 診断用および治療用標的としてのsgk1 |
WO2005084702A1 (ja) * | 2004-03-02 | 2005-09-15 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
WO2005118832A2 (en) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl) |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
EP2014651A1 (de) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Verbindungen und Verfahren zur Modulierung von Rho-GTPasen |
DE102008010361A1 (de) | 2008-02-18 | 2009-08-20 | Merck Patent Gmbh | sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen |
DE102008010363A1 (de) | 2008-02-18 | 2009-08-20 | Lang, Florian, Prof. Dr.med. | Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen |
DE102008010362A1 (de) | 2008-02-18 | 2009-08-20 | Florian Prof. Dr. Lang | Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen |
DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
CN107875153A (zh) * | 2017-11-16 | 2018-04-06 | 上海壹志医药科技有限公司 | 去甲白屈菜红碱的药物用途 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107297A (en) * | 1976-12-11 | 1978-08-15 | The Kitasato Institute | Antibiotic compound |
US5137912A (en) * | 1991-01-28 | 1992-08-11 | National Science Council Of Republic Of China | Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug |
US5242397A (en) * | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
EP0657164A1 (de) * | 1993-12-11 | 1995-06-14 | Ciba-Geigy Ag | Staurosporinderivate enthaltende Arzneimittel |
WO1997007081A2 (en) * | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
WO1997045397A1 (en) * | 1996-05-30 | 1997-12-04 | Hoechst Marion Roussel, Inc. | Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors |
EP0887081A2 (de) * | 1997-06-27 | 1998-12-30 | Smithkline Beecham Corporation | Humäne Serumglucocorticoidregulierte Kinase, ein Ziel für chronischer Nierenerkrankung |
EP0889127A1 (de) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/Threonine Protein Kinase (H-SGK2) |
WO1999002532A2 (en) * | 1997-07-07 | 1999-01-21 | Novartis Ag | Partially hydrogenated polycyclic compounds |
US5874464A (en) * | 1995-01-13 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Conformationally constrained diacylglycerol analogues |
-
1999
- 1999-04-20 DE DE19917990A patent/DE19917990A1/de not_active Ceased
-
2000
- 2000-04-19 EP EP00922655A patent/EP1171131A1/de not_active Withdrawn
- 2000-04-19 CZ CZ20013778A patent/CZ20013778A3/cs unknown
- 2000-04-19 SK SK1497-2001A patent/SK14972001A3/sk unknown
- 2000-04-19 HU HU0200819A patent/HUP0200819A3/hu unknown
- 2000-04-19 JP JP2000611917A patent/JP2002542196A/ja active Pending
- 2000-04-19 KR KR1020017013336A patent/KR100718900B1/ko not_active IP Right Cessation
- 2000-04-19 CN CN00807959A patent/CN1351496A/zh active Pending
- 2000-04-19 MX MXPA01010588A patent/MXPA01010588A/es not_active Application Discontinuation
- 2000-04-19 AU AU42972/00A patent/AU779941B2/en not_active Ceased
- 2000-04-19 PL PL352547A patent/PL198427B1/pl unknown
- 2000-04-19 BR BR0009914-7A patent/BR0009914A/pt not_active Application Discontinuation
- 2000-04-19 RU RU2001131351/15A patent/RU2288718C9/ru not_active IP Right Cessation
- 2000-04-19 CA CA002369078A patent/CA2369078A1/en not_active Abandoned
- 2000-04-19 UA UA2001117896A patent/UA79066C2/uk unknown
- 2000-04-19 WO PCT/EP2000/003578 patent/WO2000062781A1/de not_active Application Discontinuation
-
2001
- 2001-10-17 NO NO20015054A patent/NO20015054L/no not_active Application Discontinuation
- 2001-10-19 ZA ZA200108610A patent/ZA200108610B/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107297A (en) * | 1976-12-11 | 1978-08-15 | The Kitasato Institute | Antibiotic compound |
US5242397A (en) * | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
US5137912A (en) * | 1991-01-28 | 1992-08-11 | National Science Council Of Republic Of China | Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug |
EP0657164A1 (de) * | 1993-12-11 | 1995-06-14 | Ciba-Geigy Ag | Staurosporinderivate enthaltende Arzneimittel |
US5874464A (en) * | 1995-01-13 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Conformationally constrained diacylglycerol analogues |
WO1997007081A2 (en) * | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
WO1997045397A1 (en) * | 1996-05-30 | 1997-12-04 | Hoechst Marion Roussel, Inc. | Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors |
EP0887081A2 (de) * | 1997-06-27 | 1998-12-30 | Smithkline Beecham Corporation | Humäne Serumglucocorticoidregulierte Kinase, ein Ziel für chronischer Nierenerkrankung |
EP0889127A1 (de) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/Threonine Protein Kinase (H-SGK2) |
WO1999002532A2 (en) * | 1997-07-07 | 1999-01-21 | Novartis Ag | Partially hydrogenated polycyclic compounds |
Non-Patent Citations (7)
Title |
---|
CAMERON N E ET AL: "Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats.", DIABETOLOGIA, (1999 SEP) 42 (9) 1120-30., XP000912296 * |
CHENG H S ET AL: "Modulation of Ca2+-dependent anion secretion by protein kinase C in norma and cystic fibrosis pancreatic duct cells.", BIOCHIMICA ET BIOPHYSICA ACTA, (1999 APR 14) 1418 (1) 31-8., XP000900908 * |
DONALDSON KENNETH; LI XIAO YANG; DOGRA SHASHI; MILLER BRIAN G; BROWN GERALDINE M: "Asbestos-stimulated tumour necrosis factor release from alveolar macrophages depends on fibre length and opsonization.", JOURNAL OF PATHOLOGY, vol. 168, no. 2, 1992, pages 243 - 248, XP000912283 * |
FRIEDMAN LILACH MIRA; MATSUDA YUZURU; LAZAROVICI PHILIP: "The microbial alkaloid toxin staurosporine blocks the phorbol ester-induced increase in beta-amyloid precursor protein in PC12 cells.", NATURAL TOXINS, vol. 5, no. 5, 1997, pages 173 - 179, XP000912203 * |
NABESHIMA T ET AL: "STAUROSPORINE FACILITATES RECOVERY FROM THE BASAL FOREBRAIN- LESION-INDUCED IMPAIRMENT OF LEARNING AND DEFICIT OF CHOLINERGIC NEURON IN RATS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,US,AMERICAN SOCIETY FOR PHARMACOLOGY AND, vol. 257, no. 2, 1 April 1991 (1991-04-01), pages 562 - 566, XP000618959, ISSN: 0022-3565 * |
SECREST R J ET AL: "Hypotensive properties of the protein kinase inhibitor, staurosporine, in normotensive and spontaneously hypertensive rats.", CLINICAL AND EXPERIMENTAL HYPERTENSION. PART A, THEORY AND PRACTICE, (1991) 13 (2) 219-34., XP000912287 * |
SMITH S E; MELDRUM B S: "THE PROTEIN KINASE C ACTIVATORS PHORBOL-12-MYRISTATE-13-ACETATE AND PHORBOL-12 13-DIBUTYRATE ARE CONVULSANT IN THE PICO-NANOMOLAR RANGE IN MICE", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 213, no. 1, 1992, pages 133 - 135, XP000912280 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074987A3 (de) * | 2001-03-21 | 2003-12-04 | Florian Lang | Quantitative diagnostische analyse der hypertonie |
CN1306040C (zh) * | 2001-03-21 | 2007-03-21 | 弗洛里安·朗 | 高血压的定量诊断分析 |
WO2002074987A2 (de) * | 2001-03-21 | 2002-09-26 | Florian Lang | Quantitative diagnostische analyse der hypertonie |
AU2002244751B2 (en) * | 2001-03-21 | 2007-01-11 | Florian Lang | Quantitative diagnostic analysis of hypertonia |
EP1389941A4 (de) * | 2001-04-27 | 2006-11-15 | Cold Spring Harbor Lab | Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstörungen durch veränderung der atypischen pkm-aktivität |
EP1389941A2 (de) * | 2001-04-27 | 2004-02-25 | Cold Spring Harbor Laboratory | Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstörungen durch veränderung der atypischen pkm-aktivität |
US7378090B2 (en) | 2001-04-27 | 2008-05-27 | The Research Foundation Of State University Of New York | Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical PKM activity |
WO2003102206A2 (de) * | 2002-06-04 | 2003-12-11 | Florian Lang | Sgk und nedd als diagnostische und therapeutische targets |
WO2003102206A3 (de) * | 2002-06-04 | 2005-02-24 | Florian Lang | Sgk und nedd als diagnostische und therapeutische targets |
WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
WO2005037773A1 (de) * | 2003-10-09 | 2005-04-28 | Merck Patent Gmbh | Acylhydrazonderivate und ihre verwendung bei der hemmung, regulierung und/oder modulation des signaltransduktion von kinasen |
US7405239B2 (en) | 2003-10-09 | 2008-07-29 | Merck Patent Gmbh | Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction |
WO2005094829A1 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
WO2005094796A2 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for interfering with fibrosis |
WO2005094796A3 (en) * | 2004-03-11 | 2006-12-28 | Merck Patent Gmbh | Methods for interfering with fibrosis |
WO2005106491A3 (en) * | 2004-04-30 | 2005-12-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
WO2005106491A2 (en) * | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
US7619115B2 (en) | 2004-06-26 | 2009-11-17 | Merck Patent Gmbh | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides |
WO2006000293A1 (de) * | 2004-06-26 | 2006-01-05 | Merck Patent Gmbh | Ortho-substituierte (3-hydroxyphenyl)-essigsäure benzyliden-hydrazide |
WO2006072354A1 (de) * | 2005-01-07 | 2006-07-13 | Merck Patent Gmbh | Quadratsäurederivate |
WO2006105850A1 (de) * | 2005-04-04 | 2006-10-12 | Merck Patent Gmbh | Acylhyclrazide als kinase inhibitoren insbesondere für sgk |
AU2006231008B2 (en) * | 2005-04-04 | 2011-04-14 | Merck Patent Gmbh | Acyl hydrazides as kinase inhibitors, in particular for SGK |
US7767716B2 (en) | 2005-04-04 | 2010-08-03 | Merck Patent Gmbh | Acyl hydrazines as kinase inhibitors, in particular for SGK |
WO2007014608A1 (de) * | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate ii |
WO2007022858A1 (de) * | 2005-08-22 | 2007-03-01 | Merck Patent Gmbh | 3-oxo-indazol-quadratsäurederivate |
WO2008086854A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | 5-([1,3,4] 0xadiaz0l-2-yl)-1h-indazol und 5-([1,3,4] thiadiaz0l-2-yl)-1h-indazol derivate als sgk-inhibitoren zur behandlung von diabetes |
DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
WO2010020305A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate für die behandlung von diabetes |
DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
DE102008059133A1 (de) | 2008-11-26 | 2010-05-27 | Merck Patent Gmbh | Difluorphenyl-diacylhydrazid-derivate |
WO2012064981A3 (en) * | 2010-11-10 | 2012-08-16 | National Jewish Health | Methods to test allergic conditions |
EP2662078A1 (de) * | 2010-11-10 | 2013-11-13 | National Jewish Health | Verfahren zur Behandlung von allergischen Zuständen |
US8802099B2 (en) | 2010-11-10 | 2014-08-12 | National Jewish Health | Methods to treat allergic conditions |
US10369194B2 (en) | 2010-11-10 | 2019-08-06 | National Jewish Health | Methods to treat allergic conditions with PIM1 kinase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
RU2288718C2 (ru) | 2006-12-10 |
NO20015054L (no) | 2001-12-14 |
AU4297200A (en) | 2000-11-02 |
MXPA01010588A (es) | 2004-09-06 |
AU779941B2 (en) | 2005-02-17 |
KR20020012172A (ko) | 2002-02-15 |
HUP0200819A3 (en) | 2009-08-28 |
UA79066C2 (en) | 2007-05-25 |
HUP0200819A2 (hu) | 2002-07-29 |
NO20015054D0 (no) | 2001-10-17 |
ZA200108610B (en) | 2002-01-02 |
JP2002542196A (ja) | 2002-12-10 |
DE19917990A1 (de) | 2000-11-02 |
KR100718900B1 (ko) | 2007-05-17 |
EP1171131A1 (de) | 2002-01-16 |
BR0009914A (pt) | 2002-01-08 |
RU2288718C9 (ru) | 2008-04-27 |
PL352547A1 (en) | 2003-08-25 |
CN1351496A (zh) | 2002-05-29 |
CZ20013778A3 (cs) | 2002-06-12 |
CA2369078A1 (en) | 2000-10-26 |
PL198427B1 (pl) | 2008-06-30 |
SK14972001A3 (sk) | 2002-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000062781A1 (de) | Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk | |
DE69535462T2 (de) | Zusammensetzung und Verfahren zur Inhibition der Filamentbildung des Amyloid-Betaproteins und seiner Neutotoxizität | |
DE69636997T2 (de) | HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN | |
DE60313125T2 (de) | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen | |
DE69637104T2 (de) | Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen | |
EP2046732B1 (de) | Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln | |
WO2004085682A2 (de) | Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza | |
EP2242738B1 (de) | Sgk1-inhibitoren zur prophylaxe und/oder therapie von viralen erkrankungen und/oder karzinomen | |
DE69624253T2 (de) | Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren | |
EP1056467B1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
EP0655242A1 (de) | Verwendung von Cumarinderivaten bei NO-induzierten Krankheiten | |
EP1313476B1 (de) | SGK3 ALS DIAGNOSTISCHEs UND THERAPEUTISCHEs TARGET | |
US20050064501A1 (en) | Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk | |
DE69607417T2 (de) | Verwendung von Batroxobin enthaltende Arzneimittel zur Behandlung und Prophylaxe von ischämischen Reperfusionsschäden | |
EP0919244A2 (de) | Kombinationspräparate für die Therapie von Tumoren | |
Erickson et al. | Altered functional expression of Purkinje cell calcium channels precedes motor dysfunction in tottering mice | |
DE2349538A1 (de) | Arzneimittel zur behandlung von lebererkrankungen | |
DE60110628T2 (de) | Antiphlogistische mittel | |
DE602004011843T2 (de) | Die myocardfunktion wiederherstellende peptidsubstanz | |
Conroy et al. | Nitroimidazole neurotoxicity: Are mouse studies predictive? | |
DE10234901A1 (de) | Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen | |
DE102004015752B4 (de) | Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen | |
EP1080192A2 (de) | Antisense-oligonukleotide zur behandlung von proliferierenden zellen | |
Petkov et al. | Synthetic Plant Growth Regulators as Possible Psychotropic Drugs: I. Behavioural Studies on Rats | |
DE102004056659A1 (de) | Abgabe von Oligonucleotiden an entzündete Schleimhaut |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00807959.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 14972001 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2369078 Country of ref document: CA Ref document number: 2369078 Country of ref document: CA Kind code of ref document: A Ref document number: 2000 611917 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-3778 Country of ref document: CZ Ref document number: 2001/08610 Country of ref document: ZA Ref document number: PA/a/2001/010588 Country of ref document: MX Ref document number: 1020017013336 Country of ref document: KR Ref document number: 200108610 Country of ref document: ZA Ref document number: IN/PCT/2001/1451/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000922655 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000922655 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017013336 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-3778 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017013336 Country of ref document: KR |